Izalontamab Brengitecan in Locally Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical <i>EGFR</i> Mutations: A Phase Ib Study
iza-bren demonstrated encouraging antitumor activity and a manageable safety profile in pretreated NSCLC patients with diverse GAs outside of classical <i>EGFR</i> mutations, especially in <i>EGFR</i> exon20ins/nonclassical and <i>HER2</i> mutations.
Authors
- Yu-Heng Zhao
- L. Chen
- Zhiyong He
- Y. Zhu
- Xue Hou
- Wenfeng Fang
- Yongsheng Wang
- Hongyun Zhao
- Yuxiang Ma
- Li Zhang
- Yan Huang
- Huaqiang Zhou
- Yongsheng Li
- Yunpeng Yang
- Sa Xiao
- Hai Zhu
Institutions
- Sun Yat-sen University (CN)
- Chongqing University (CN)
- Sichuan University (CN)
- Aimmune Therapeutics (United Kingdom) (GB)
- Chengdu University (CN)
- Buchang Pharma (China) (CN)
- Sun Yat-sen University Cancer Center (CN)
- Fujian Provincial Cancer Hospital (CN)
- Chongqing Cancer Hospital (CN)
- State Key Laboratory of Oncology in South China
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1200/jco-25-01929
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00